Global Women’s Healthcare Market: Growing incidence of chronic as well as infectious disease among female population will drive the women health care market growth during the forecast period.

The global women’s healthcare market is projected to reach USD 22.72 billion by 2027 from USD 11.24 billion in 2020, at a CAGR of 10.6% during the forecast period (2020-2027). Growing incidence of chronic as well as infectious disease among female population will drive the women health care market growth during the forecast period. According to the American Institute for Cancer Research, breast cancer is the most commonly occurring cancer among women, accounting for over 2 million new cases in 2020. Additionally, in 2020, around 268,600 new cases of invasive breast cancer are estimated in the U.S. women. Growing adoption of unhealthy diet and lifestyle changes will increase the disease burden thereby, augmenting the women health devices industry growth. Moreover, increasing prevalence of infectious disease among females in the underdeveloped economies due to unhygienic environment will favour business growth.

Furthermore, technological advancement coupled with increasing demand for minimally invasive procedures will render positive impact on the business growth. Numerous efforts undertaken by government and other organizations to raise awareness regarding women’s health, management to reduce disease burden and promote availability of advanced technologies for diseases diagnosis and treatment will further drive industry growth. For instance, the Office on Women's Health (OWH) addresses critical women's health issues by educating patients and healthcare professionals, advancing policies as well as supporting innovative programs. However, high cost of devices along with lack of awareness among women especially in underdeveloped economies may impede women health devices industry growth to certain extent over the forecast timeframe.

According to the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million in 2050. Moreover, breast cancer, cardiovascular diseases, and mental diseases significantly contribute to the burden of non-communicable diseases. Women most likely start to undergo menopause after the age of 48 wherein they experience hormonal changes that affect the quality of life. About 73.0% of postmenopausal women experience hot flashes. The Society of Obstetricians and Gynaecologists of Canada (SOGC) estimated that 80.0% of women suffer from at least one symptom of menopause such as mood swings, interrupted sleep, and irritability.

The market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), and Apothecus Pharmaceutical (US).

The global women’s healthcare market is segmented into five major regions, namely, North America, Europe, APAC, Latin America, and the Middle East & Africa. In 2020, North America (US and Canada) was the largest and the fastest-growing regional market for women’s healthcare. The major factors supporting market growth include the growing prevalence of PCOS and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. Also, the high awareness and understanding regarding contraceptives among American women and the easy access to modern contraception as compared to developing countries propel the market growth in this region